[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prosthetic-heart-valve\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prosthetic-heart-valve":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100642197","optimizing-anticoagulation-in-pregnancies-with-mechanical-heart-valves-100642197",false,"NCT07658989","Optimizing Anticoagulation in Pregnancies With Mechanical Heart Valves","A Prospective Multicenter Cohort Pilot Study Comparing Antithrombotic Regimens in Pregnancies With Mechanical Heart Valves","Inclusion Criteria:\n\n1. Pregnant individuals with one or more MHVs\n2. Who consent to participate\n3. Are 18 years or older and\n4. Less than 12 weeks gestation\n\nExclusion Criteria:\n\n1. Have a platelet count less than 50 x 10(9)\u002FL as there is an increased risk of bleeding with thrombocytopenia, and\u002For\n2. Have active bleeding defined as bleeding resulting in a hemoglobin reduction ≥10 g\u002FL or in hemodynamic instability.\n3. Have new valve thrombosis identified immediately prior to pregnancy","FEMALE","18 Years","45 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this pilot study is to collect data on pregnancies with mechanical heart valves to see if using a blood thinner called low molecular weight heparin (LMWH) and low dose aspirin (LDA) is comparable to warfarin\u002Fvitamin K antagonist (VKA) to reduce the chance of clotting around the mechanical valve and improve survival. The study is a pilot study as the study investigators need to ensure that the blood levels needed for adequate amounts of LMWH and warfarin can be maintained during pregnancy to be able to compare LMWH and aspirin to warfarin. If this study shows that we can collect the tests that are needed for a larger study, the individuals' information who participated in this pilot study will be moved to the larger study. The larger study will compare survival, clot development and cardiac function as well as safety of these two common blood thinners.",[27,28,29],"Pregnancy","Prosthetic Heart Valve","Anticoagulant Therapy",[27,31,32,33,34,35],"Prosthetic heart valve","Anticoagulant therapy","Low molecular weight heparin","warfarin","vitamin K antagonist","RECRUITING","2026-06-15",{"date":39,"type":40},"2026-06-22","ACTUAL",{"date":42,"type":40},"2026-05-26",{"date":44,"type":21},"2030-12",{"name":46,"class":47},"Mount Sinai Hospital, Canada","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":48},"100607729","sacubitrilvalsartan-in-patients-with-prosthetic-heart-valves-with-heart-failure-and-reduced-ejection-fraction-100607729","NCT07192341","Sacubitril\u002FValsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction","Effect of Sacubitril\u002FValsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Both sexes.\n* Patients with a history of prosthetic heart valves.\n* Patients diagnosed with heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40% with New York Heart Association (NYHA) functional class II-IV.\n\nExclusion Criteria:\n\n* Hemodynamic instability.\n* Use of a circulatory auxiliary circulation device.\n* Severe hepatic \\[alanine aminotransferase (ALT) \\>120 U\u002FL\\] and renal insufficiency \\[estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\\].\n* Blood pressure \\\u003C100\u002F60 mmHg.\n* Serum potassium \\>5.3 mmol\u002FL.\n* Severe pulmonary hypertension.\n* Malignant arrhythmia.\n* Malignant tumor.\n* Known history of hereditary or primary angioedema.\n* Serious adverse drug reactions or serious complications over the course of treatment.","ALL",{"count":58,"type":21},220,[24],"This study aims to evaluate the effect of sacubitril\u002Fvalsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).",[62,28,63,64],"Sacubitril\u002FValsartan","Heart Failure","Reduced Ejection Fraction","2025-09-27",{"date":67,"type":40},"2025-09-30",{"date":65,"type":40},{"date":70,"type":21},"2026-02-01",{"name":72,"class":47},"Kafrelsheikh University"]